{"id":"intratumoral-injections-of-l19il2","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2109608","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By targeting the EDB domain of fibronectin, L19IL2 selectively binds to tumor-associated blood vessels, allowing IL-2 to be delivered directly to the tumor site. This localized delivery of IL-2 stimulates the expansion and activation of tumor-specific T cells, leading to an anti-tumor immune response.","oneSentence":"L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:55:21.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT07227350","phase":"PHASE2","title":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-02","conditions":"Locally Advanced Basal Cell Carcinoma","enrollment":180},{"nctId":"NCT07228442","phase":"PHASE2","title":"L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-02","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07227870","phase":"PHASE2","title":"L19IL2/TNF in Patients With Basal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-02","conditions":"Locally Advanced Basal Cell Carcinoma","enrollment":92},{"nctId":"NCT03567889","phase":"PHASE3","title":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2018-09-20","conditions":"Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID","enrollment":186},{"nctId":"NCT06284590","phase":"PHASE2","title":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2024-07-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":162},{"nctId":"NCT02938299","phase":"PHASE3","title":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2016-07-01","conditions":"Malignant Melanoma","enrollment":214},{"nctId":"NCT04362722","phase":"PHASE2","title":"Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients","status":"UNKNOWN","sponsor":"Philogen S.p.A.","startDate":"2020-09-02","conditions":"Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell","enrollment":40},{"nctId":"NCT02076633","phase":"PHASE2","title":"Intratumoral Administration of L19IL2/L19TNF","status":"COMPLETED","sponsor":"Philogen S.p.A.","startDate":"2012-12","conditions":"Malignant Melanoma, Skin","enrollment":21},{"nctId":"NCT01253096","phase":"PHASE2","title":"Intratumoral Application of L19IL2 in Patients With Malignant Melanoma","status":"COMPLETED","sponsor":"Philogen S.p.A.","startDate":"2010-04","conditions":"Malignant Melanoma","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Intratumoral injections of L19IL2","genericName":"Intratumoral injections of L19IL2","companyName":"Philogen S.p.A.","companyId":"philogen-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response. Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}